Canadian Micro Cap Gets Boost Following Study Findings

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, November 22, 2022

A Calgary-based biotech company is turning heads on Tuesday after it was announced that a recent study showed its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment, cis-platinum, according to the release. This sent shares of Marvel Biosciences Corp. (TSXV:MRVL) higher on the news.

Marvel Biosciences Corp is a life sciences company focused on the discovery and the development of a synthetic derivative compound of a known proven drug. It has developed several new patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, ADHD and addiction), cancer, and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis.

Traders bought up shares of this micro cap until the price reached $0.17/share (+6.25%) at the early session high. This move was a strong continuation of the success this stock has had over the course of the last month.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.